Fresenius Medical Care and SEHA Enter Into Exclusive Agreement to Serve Dialysis Patients in Abu Dhabi

BAD HOMBURG, Germany, September 3, 2010 - Fresenius Medical Care AG & Co. KGaA (Frankfurt Stock
Exchange: FME / New York Stock Exchange: FMS), the world's largest provider
of dialysis products and services, today announced its signing of a
nonbinding memorandum of understanding with Abu Dhabi Health Services Co.
PJSC (SEHA), the public provider of health care services, for exclusive
management of its dialysis facilities in the emirate of Abu Dhabi, United
Arab Emirates.

The agreement will enable Fresenius Medical Care to initiate activities
in a key Middle Eastern market. It also is aimed as a key aspect of both
groups' strategy to expand their business in the region. Both entities have
agreed not to disclose financial details of the transaction under discussion.

"Initiating patient care operations in the Middle East has
been a defined path in our overall growth strategy, and we are convinced that
the contract with SEHA is an excellent basis for the growth of Fresenius
Medical Care in this region. The contract will allow our company to
significantly strengthen its sales and distribution network and expand our
presence in this key market," said Fresenius Medical Care's Dr. Emanuele
Gatti, CEO for Europe, Latin America, the Middle East and Africa.

Saif Bader Al Qubaisi, managing director and chairman of SEHA,
commented, "We are delighted to have engaged Fresenius Medical Care as our
exclusive partner in the management of our renal patients. We look forward to
benefiting from the knowledge and skills of the leader in this sector in
building a world-class patient care organization that delivers on its promise
of high-quality health care services for the people. We also look forward to
pursuing other development activities in the region with our partner
Fresenius Medical Care."

Dr. Ali Abdulkareem Al Obaidli, chief of clinical affairs for
SEHA and a practicing renal specialist, added, "This is good news for Abu
Dhabi. Bringing in the world's best providers and managers is part of our
business strategy. This partnership will result in improved service levels
and better outcomes for our dialysis patients."

Fresenius Medical Care is the world's largest integrated provider of
products and services for individuals undergoing dialysis because of chronic
kidney failure, a condition that affects more than 1.89 million individuals
worldwide. Through its network of 2,599 dialysis clinics in North America,
Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care
provides dialysis treatment to 202,414 patients around the globe. Fresenius
Medical Care also is the world's leading provider of dialysis products such
as hemodialysis machines, dialyzers and related disposable products.
Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3)
and the New York Stock Exchange (FMS, FMS/P).

For more information about Fresenius Medical Care, visit the company's
website at www.fmc-ag.com.

About the SEHA HealthSystem and Abu Dhabi Health Services Co. PJSC (SEHA)

Abu Dhabi Health Services Co. PJSC is an independent, public joint-stock
company wholly owned by the government of Abu Dhabi and created to develop
the curative activities of the emirate's public health care system. The
company owns and operates all the public hospitals and clinics in the emirate
of Abu Dhabi which together make up the SEHA HealthSystem. Its holdings
include 12 hospitals with 2,644 beds, 62 ambulatory care, family care and
urgent care centers and two blood banks. SEHA is one of the largest
integrated health care providers in the Middle East, employing 16,500
doctors, nurses, ancillary care and administrative personnel. SEHA means
"health" in Arabic. Visit the SEHA website at www.seha.ae.

This release contains forward-looking statements that are
subject to various risks and uncertainties. Actual results could differ
materially from those described in these forward-looking statements due to
certain factors, including changes in business, economic and competitive
conditions, regulatory reforms, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties are
detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA
does not undertake any responsibility to update the forward-looking
statements in this release.

    Joachim Weith
    Corporate Communications and Governmental Affairs
    Tel.: +49-6172-6082101
    Fax: +49-6172-6082294
    E-mail: pr@fmc-ag.com

    www.fmc-ag.com

Joachim Weith, Corporate Communications and Governmental Affairs, Tel.: +49-6172-6082101, Fax: +49-6172-6082294, E-mail: pr at fmc-ag.com